Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1
暂无分享,去创建一个
Brendan Larder | Kaneo Yamada | Tsuyoshi Oishi | Hiroshi Yoshikura | Wataru Sugiura | Yoshiyuki Nagai | Kurt Hertogs | K. Hertogs | B. Larder | W. Sugiura | Y. Nagai | Z. Matsuda | Y. Yokomaku | N. Takata | M. Matsuda | H. Yoshikura | T. Shiino | M. Tatsumi | Masashi Tatsumi | Masakazu Matsuda | Yoshiyuki Yokomaku | Zene Matsuda | Aiko Okano | Teiichirou Shiino | Hanae Abumi | Noboru Takata | Satoshi Shirahata | Kaneo Yamada | T. Oishi | H. Abumi | A. Okano | S. Shirahata
[1] N. Roberts. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. , 1995, AIDS.
[2] S. Gulnik,et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.
[3] D. Ho,et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.
[4] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[5] R. Swanstrom,et al. The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. , 1999, AIDS research and human retroviruses.
[6] D. Lamarre,et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.
[7] N. Shen,et al. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.
[8] D. Ho,et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.
[9] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[10] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.
[11] M. Ott,et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.
[12] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[13] C. Debouck,et al. The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.
[14] D. Ho,et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.
[15] Philip R. Johnson,et al. Antibodies to the putative SIV infection‐enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques , 1995, AIDS.
[16] S. Gulnik,et al. Drug resistance mutations can affect dimer stability of HIV‐1 protease at neutral pH , 1999, Protein science : a publication of the Protein Society.
[17] D. Ho,et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. , 1998, The Journal of infectious diseases.
[18] B. Berkhout. HIV-1 Evolution under Pressure of Protease Inhibitors: Climbing the Stairs of Viral Fitness , 1999, Journal of Biomedical Science.
[19] B. Ho,et al. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.
[20] J. Louis,et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.
[21] L J Davis,et al. Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[22] N. Mochizuki,et al. An infectious DNA clone of HIV type 1 subtype C. , 1999, AIDS research and human retroviruses.
[23] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[24] R. Myers,et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.
[25] I B Duncan,et al. Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.
[26] P. Darke,et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[28] I. Weber,et al. Molecular mechanics analysis of drug-resistant mutants of HIV protease. , 1999, Protein engineering.
[29] Marianne Manchester,et al. Complete mutagenesis of the HIV-1 protease , 1989, Nature.
[30] Z. Matsuda,et al. A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[31] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[32] M. Murcko,et al. Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .
[33] D. R. Kuritzkes,et al. Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.